JP Morgan Chase
NRIX icon

JP Morgan Chase’s Nurix Therapeutics NRIX Stock Holding History

JP Morgan Chase’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$739K Buy
50,357
+3,069
+6% +$50.9K ﹤0.01% 4774
2025
Q4 		$897K Sell
47,288
-245
-0.5% -$3.52K ﹤0.01% 4684
2025
Q3 		$439K Sell
47,533
-2,949
-6% -$30.6K ﹤0.01% 5111
2025
Q2 		$575K Buy
50,482
+4,792
+10% +$51.8K ﹤0.01% 4701
2025
Q1 		$543K Buy
45,690
+14,795
+48% +$247K ﹤0.01% 4711
2024
Q4 		$582K Sell
30,895
-37,253
-55% -$854K ﹤0.01% 4957
2024
Q3 		$1.53M Buy
68,148
+31,352
+85% +$710K ﹤0.01% 4203
2024
Q2 		$768K Buy
36,796
+2,472
+7% +$38.5K ﹤0.01% 4435
2024
Q1 		$505K Sell
34,324
-13,666
-28% -$147K ﹤0.01% 4788
2023
Q4 		$495K Sell
47,990
-4,901
-9% -$33.6K ﹤0.01% 4800
2023
Q3 		$416K Buy
52,891
+64
+0.1% +$584 ﹤0.01% 4586
2023
Q2 		$528K Buy
52,827
+17,092
+48% +$174K ﹤0.01% 4454
2023
Q1 		$317K Sell
35,735
-53,361
-60% -$556K ﹤0.01% 4777
2022
Q4 		$979K Buy
89,096
+60,822
+215% +$734K ﹤0.01% 4055
2022
Q3 		$368K Sell
28,274
-101,251
-78% -$1.6M ﹤0.01% 4638
2022
Q2 		$1.64M Buy
129,525
+9,009
+7% +$102K ﹤0.01% 3698
2022
Q1 		$1.69M Buy
120,516
+30,664
+34% +$544K ﹤0.01% 3888
2021
Q4 		$2.6M Buy
89,852
+31,867
+55% +$966K ﹤0.01% 3646
2021
Q3 		$1.74M Buy
57,985
+29,148
+101% +$900K ﹤0.01% 3895
2021
Q2 		$765K Buy
28,837
+16,938
+142% +$497K ﹤0.01% 4455
2021
Q1 		$370K Buy
11,899
+6,668
+127% +$252K ﹤0.01% 4858
2020
Q4 		$172K Buy
5,231
+1,091
+26% +$36.2K ﹤0.01% 4858
2020
Q3 		$138K Buy
+4,140
New +$104K ﹤0.01% 4556

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

JP Morgan Chase's NRIX Position: Q1 2026 in Review

JP Morgan Chase increased its Nurix Therapeutics (NRIX) stake by 6.5% in Q1 2026, buying an estimated $50.9K and bringing the position to 50,357 shares worth $739K. The position accounts for ﹤0.01% of the portfolio, ranked #4774.

JP Morgan Chase first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.6M in Q4 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • JP Morgan Chase held 50,357 shares of Nurix Therapeutics worth $739K as of Q1 2026.
  • JP Morgan Chase bought 3,069 Nurix Therapeutics shares in Q1 2026, an estimated $50.9K.
  • Nurix Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4774 holding.
  • JP Morgan Chase first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Nurix Therapeutics position peaked at $2.6M in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.